Showing papers by "Chungyeul Kim published in 2005"
TL;DR: Whether the RS assay predicts prognosis, response to tamoxifen, or both, is determined, and a subset of individual genes (Cyclin B1, Survivin, MYBL2, STK15, Ki-67, PR, and GSTM1), the proliferation gene group score and the RS were significantly associated with DRFS in the placebo pts.
Abstract: 510 Background: The 21 gene Recurrence Score (RS) assay (Oncotype DX) has been validated to quantify the risk of distant recurrence in tamoxifen (tam)-treated pts with N-, ER+ breast cancer. To determine whether the RS assay predicts prognosis, response to tamoxifen, or both, we studied the pts randomized to placebo and tam in NSABP B-14. Methods: Pts were eligible if tumor blocks were available and contained at least 5% invasive cancer. Expression was quantified by the pre-specified 21 gene RT-PCR assay, and the RS was calculated by the pre-specified algorithm. Cox models were used to evaluate the association between potential predictive variables and distant-recurrence free survival (DRFS). Results: There were 645 evaluable pts (355 placebo and 290 tam). A subset of individual genes (Cyclin B1, Survivin, MYBL2, STK15, Ki-67, PR, and GSTM1), the proliferation gene group score and the RS were significantly associated with DRFS in the placebo pts (p<0.05). ER was not associated with DRFS in the placebo pts...
104 citations
TL;DR: Methods are being developed to optimize the use of RNAs extracted from FPETs for high-throughput gene expression profiling assays, and real-time reverse transcription-polymerase chain reaction is the method of choice for gene-expression profiling.
Abstract: In order to improve prognostic and predictive markers of breast cancer, assessment of formalin-fixed paraffin-embedded tissue is important However, there are problems associated with the use of paraffin-embedded tissue for gene-expression profiling, especially when analyzing older samples Paiket al discuss the advantages of using real-time reverse transcription-polymerase chain reaction (RT-PCR) for gene-expression level quantification and describe how the Oncotype DX™ RT-PCR assay, among others, has helped to circumvent some of these challenges Breast cancer is a heterogenous disease in terms of both clinical behavior and molecular characteristics To develop prognostic and predictive markers for breast cancer, it would be useful to be able to analyze formalin-fixed paraffin-embedded tissue (FPET) collected and banked from completed clinical trials RNAs extracted from FPETs are chemically modified and fragmented, and are therefore not ideal substrates for gene-expression profiling assays However, methods are being developed to optimize the use of such RNAs for high-throughput gene expression profiling assays For microarray analysis, existing methods may be adequate for fresh FPET, but they do not work well with older FPET For older samples, real-time reverse transcription-polymerase chain reaction is the method of choice for gene-expression profiling
97 citations
Patent•
15 Dec 2005
TL;DR: In this article, a method of screening for markers useful in predicting the efficacy of a specified cancer was proposed, which includes constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data.
Abstract: The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow up data. In addition, the present invention provides a method of treating breast cancer that includes measuring the expression levels or amplification of HTPAP in a patient having breast cancer and then providing a patient having increased levels of HTPAP expression or HTPAP amplification with therapeutic quantities of at least one compound that interferes with the phosphatidic acid phosphatase activity of HTPAP. The present invention also encompasses a method of treating breast cancer that includes screening a breast cancer patient for amplification of the cMYC gene and then treating a patient having amplification of the cMYC gene with therapeutic quantities of a compound that interferes with HER2 signaling.
18 citations